Kornimate/medical-research-clean huggingface dataset:
non absorbable clips vs endoloops in laproscopic appendicectomy

Conditions: Appendicitis

Summary: a) compare between nonabsorbable polymeric clips and endoloop ligatures regarding: 1. technical difficulties. 2. operation time. 3. cost effectiveness. 4. postoperative complications. 5. inpatient stay.

laparoscopic appendectomy is gradually evolving as the 'gold standard' in the treatment of acute appendicitis, especially in the obese, elderly, and in cases where the diagnosis is uncertain . there are clear benefits with the laparoscopic approach in terms of decreased pain and faster recovery than the open approach . however, disadvantages like a higher incidence of intra-abdominal collection, longer operating time, and higher costs have been documented. these may be dependent on the technique of appendicular stump closure. therefore, the technique for appendiceal stump closure is crucial in laparoscopic appendectomy. laparoscopic appendectomy was first described by semm in 1983 and is currently preferred approach for an appendectomy for many surgeons. numerous methods of stump closure have been used, like intracorporeal suturing of the stump endoloop application, endostapler application ligasure customized titanium clip application, and, more recently, using nonabsorbable plastic clips . many of these techniques are either time consuming or expensive, or not available universally.

Eligibility criteria:
inclusion criteria: * . able to give informed consent for inclusion in the study * age of the patient : any age exclusion criteria: * • intraoperative decision to convert to open appendicectomy * primary open appendicectomy * unable to give informed consent for participation in the study
preoperative identification of the histologically "vulnerable" plaque using non-invasive imaging, biomechanical assessment and baroreflex evaluation in patients with severe carotid stenosis

Conditions: Carotid Artery Plaque; Diagnosis

Summary: carotid artery stenosis due to atherosclerotic plaques accounts for an important cause of ischemic stroke. current research seeks to risk stratify asymptomatic patients by characterizing rupture-prone plaques. currently no single imaging modality can reliably identify those plaques before surgery. recently, the 3d ultrasound (us) and the assessment of the mechanical stress on the vessel wall have been proposed as non-invasive tools that could play a role in the diagnostic work-up. data of histological validation, however, are still needed. in this research, 3d us, non-invasive elastography, finite element analysis of computed tomography angiography images and the study of the autonomic cardiovascular control will be used to identify preoperatively the vulnerable plaque in patients undergoing carotid endarterectomy. the results will be compared to that of histology of the removed plaque, aiming to provide a validation to each method for a possible application in the daily practice.


Eligibility criteria:
inclusion criteria: * age above 18 years; * signed informed consent. exclusion criteria: * medical conditions limiting expected survival to \<1 year; * patients with significant uncontrolled or unstable medical condition (heart failure or angina pectoris class nyha iii-iv, cardiac surgery in the previous 30 days, left ventricular ejection fraction \<30%, severe chronic obstructive pulmonary disease, myocardial infarction in the previous 30 days, coronary heart disease with revascularization indication, that is, the common trunk or more than two coronary vessels); * tracheostomy; * paralysis of the laryngeal nerve contralateral to the carotid stenosis; * women of childbearing potential; * inability to give informed consent; * patients presenting contraindications to perform a cta examination of neck vessels with contrast medium; * patients with medical history of stroke/tia within the previous 6 months.

Keywords: carotid stenosis ultrasonic imaging finite element analysis
pilot study on the evaluation of the effectiveness of a virtual reality device on anxiety during procedural sedation in traumatology in emergency department

Conditions: Reality Device; Reduction Procedure; Fracture; Dislocation

Summary: the aim of this study is to evaluate the efficiency of a reality device and a virtual hypnosis software to reduce the anxiety during reduction procedure in traumatology in an emergency department. these devices have recently been evaluated in the management of pain and anxiety in different specialties but never in the context of analgesia-sedation protocols in emergencies.


Eligibility criteria:
inclusion criteria: * patient aged 18 years or older * patient suffering from one of the following traumatic pathologies requiring a technical procedure in the emergency room shoulder dislocation ankle dislocation elbow dislocation wrist dislocation reducible fractures * no contraindication to virtual reality * no contraindication to morphine, ketamine, propofol, paracetamol, nefopam and meopa * patient having given oral, free and informed consent exclusion criteria: * patients suffering from mono or binocular blindness * patient under the influence of alcohol or psychotropic drugs * patient presenting a psychosis and/or a state of agitation, and/or a state of confusion. * patient presenting a hemodynamic, respiratory or neurological failure * patient with at least one of the following symptoms at the time of inclusion in the study: headache, dizziness, nausea, vomiting * persons benefiting from reinforced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection (guardianship and trusteeship) and finally patients in a vital emergency situation. * pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal/mechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy) * concurrent participation in another clinical research study whose objective is the evaluation of anxiety and/or pain
relation between oculocardiac reflex and laryngospasm

Conditions: Eye Abnormalities; Arrythmia

Summary: the aim of this study is to evaluate whether there is a significant relation between various arrhythmias during the surgeon's stretching the eye muscles and laryngospasm and emergence agitation in strabismus surgeries

background: laryngospasm is one of the serious complications that can be seen in perioperative period, especially during anesthesia induction and extubation. the aim of this study is to evaluate whether there is a significant relation between various arrhythmias during the surgeon's stretching the eye muscles and laryngospasm and emergence agitation in strabismus surgeries

Eligibility criteria:
inclusion criteria: * scheduled for the strabismus surgery * asa 1-2 patients * 2-65 yo patients exclusion criteria: * patients with kidney, cardiac diseases * being treated with sedative or anticonvulsant drugs * asa 3-4 patients * patients with upper respiratory tract disease in the last 2 weeks * patients who do not want to participate in the study * patients with behavioral disorders

Keywords: strabismus surgery laryngospasm oculocardiac reflex emergence agitation
apogee, a heartware hvad destination product surveillance registry (psr) platform

Conditions: Chronic Heart Failure

Summary: medtronic is sponsoring the apogee study to further enhance scientific understanding of the implant procedure, optimized blood pressure management, and anticoagulation/ antiplatelet therapy in patients receiving a medtronic heartware™ ventricular assist device (hvad™) for destination therapy. the apogee study is conducted within medtronic's product surveillance platform.

the apogee study is a prospective, observational, post-market, on-label, multi-site study in destination therapy patients. patients participating in the medtronic destination therapy (dt) post approval study (pas) (nct03681210) are eligible for participation in apogee. patients enrolled in apogee will be followed under the apogee study for one-year post-implant. after participation in apogee ends, patients will remain enrolled in dt pas and will continue to be followed as outlined in the dt pas protocol. the total estimated study duration is 33 months.

Eligibility criteria:
inclusion criteria: * subjects consented to participate in dt pas are eligible for participation in apogee. exclusion criteria: * there are no exclusion criteria unique to apogee.
evaluation of fluid resuscitation in children with cancer with severe sepsis / septic shock

Conditions: Cancer; Septic Shock; Other Fluid Overload

Summary: retrospective study to evaluate the characteristics of patients and of fluid resuscitation during intensive care unit hospitalization of patients under septic chock.


Eligibility criteria:
inclusion criteria: * patients admitted between jan/2009 and dec/2010 * patients with septic chock diagnosis exclusion criteria: -
the efficacy of budesonide/formoterol in cough variant asthma

Conditions: Cough Variant Asthma

Summary: cough variant asthma (cva), subtype of bronchial asthma, is considered to be one of the most common causes of chronic cough in different cough guidelines of united states, europe, china and other countries. from a multicenter survey in china, over one third of chronic cough is caused by cva, which is higher than western countries. cva differs from classic asthma, usually manifesting a symptom of only coughing without wheezing or dyspnea and particularly coughing at night. with less clinical manifestation and medical intervention, cva patients are easily be neglected and misdiagnosed, and 30-40% of them will develop to typical asthma in the next few years. currently there's no specific therapy recommendation for cva in gina. although cough guidelines in china recommend that cva patients should be treated as typical asthma, no recommendation on details about ics/laba dosage and duration. there are only a few sporadic cva therapy researches with small sample size. two studiesfound that cva patients can't get cough symptom relief even after treating by low dose of ics/laba for 3 months. some patients' cough symptom relapses during the 24-week follow-up phase after treating by ics/laba for 3 months. overall, the best treatment of cva is not yet clear. gina 2018 emphasize that asthma need long-term management. euro-smart study found that budesonide/formoterol 2 inhalation twice daily plus as needed can reduce daytime asthma symptoms and night-time awakenings, as well as reduce exacerbation risk more than 1 inhalation twice daily. based on the above reasons, we assume that increase the dosage of ics/laba can decrease relapse rate in cva patients with severe cough. this multi-center, randomized, controlled clinical trial can help to clarify the best dosage of budesonide/formoterol of cva in china.


Eligibility criteria:
inclusion criteria: * outpatients, with age ≥18，≤70 years old. * diagnose with cva * css(cough symptom score, daytime + nighttime) ≥ 3 points exclusion criteria: * participated in any interventional clinical trial during the last 90 days. * pregnancy * associated with a clear history of other lung diseases, or combined with other systems severe illness. * a abuse history of alcohol or narcotic drug, or have a mental history, confrontation personality, adverse motives, suspicious or other emotional or intellectual problems that may affect the informed validity of the study * with a history of upper respiratory tract infection acute exacerbation within 4 weeks before enrolment. * clinical abnormalities associated with symptoms in chest radiology. * smokers * on medications of acei or arb * not suitable for study observation judged by investigators
state trial: sustained attention training to enhance sleep - remote

Conditions: Insomnia Chronic

Summary: this study is a validation study to document the acceptability of the tonic and phasic alertness training (tapat) program in older adults with chronic late-life insomnia. the goal of this study is to employ a computerized attention-training program, tapat, designed for chronic late-life insomnia in a remote, randomized, controlled trial to assess feasibility and initial efficacy in this population.


Eligibility criteria:
inclusion criteria: * participant must be 55 years of age or older. * participant must meet criteria for clinical insomnia - moderate severity based on the insomnia severity index. * participant must be a fluent english speaker. * participant must have adequate visual, auditory, and motor capacity to use computerized intervention. * participant must have a computer and access to the internet. exclusion criteria: * participants with untreated psychiatric conditions, including substance abuse/dependence disorders, untreated obstructive sleep apnea, diagnosis of other sleep disorders (e.g., restless legs syndrome), recent hospitalization, ongoing chemotherapy or other cancer treatment, and concurrent engagement in another insomnia treatment. * participants enrolled in another concurrent research study. * participants using computer-based cognitive training programs or has used them within a month of the consent date.
radiofrequency ablation in patients with large cervical heterotopic gastric mucosa and globus sensation

Conditions: Symptomatic Heterotopic Gastric Mucosa

Summary: symptomatic heterotopic gastric mucosa also known as cervical inlet patch (cip) may be present in varying shapes and causes symptoms of laryngopharyngeal reflux like globus sensations, hoarseness and chronic cough. unfortunately, argon plasma coagulation, standard treatment of small symptomatic cip, is limited for large heterotopic gastric mucosa due to concerns of stricture formation. therefore, the investigators aimed to investigate the effect of radiofrequency ablation (rfa), a novel minimal-invasive ablation method, in the treatment of large symptomatic cip.


Eligibility criteria:
inclusion criteria: * negative ppi trial, ph-metry without correlation on globus sensation, prior high-resolution manometry exclusion criteria: * not willing to participate in follow up
programmed cell death protein-1 (pd-1) monoclonal antibody for ebv-hlh and caebv as first-line therapy

Conditions: EBV Infection

Summary: ebv-hlh and caebv are both caused by ebv infection, part of them can rapidly lead to a syndrome of severe, life-threatening hyper-inflammation, with poor prognosis. currently, the most effective treatment remains unknown. this study is trying to evaluate the efficacy and safety of pd-1 monoclonal antibody as a first-line therapy for ebv-hlh and caebv.

eligible patients who were diagnosed with ebv-hlh or caebv, age between 12 and 70 years, were enrolled in this study. all of them need to sign the informed consent first. pd-1 monoclonal antibody 200mg is infused intravenously once for patients whose age \>=18 years, or age \ =40kg. while for patients age \<18 years, the dose of pd-1 monoclonal antibody is 3mg/kg. besides, optimal supportive care is necessary. ruxolitinib and/or low-dose glucocorticoid can be used to reduce inflammation. cerebrospinal fluid parameters are examined, and methotrexate 15mg combined with dexamethasone will be intrathecal injected without contraindications. clinical and laboratory indicators are investigated weekly to evaluate the efficacy and toxicity. if patients achieve partial response/complete response within 14 days after pd-1 monoclonal antibody, the clinical observations are stopped. if not, the observation period is prolonged to 21 days. if disease progress at day 21, this study is terminated, and the patient should be transfer to other treatments as soon as quickly.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria of ebv-hlh or caebv. 2. newly diagnosed patients. 3. eastern cooperative oncology group score 0-3. 4. total bilirubin \<= 10 times of upper limit of normal (except for those caused by ebv-hlh or caebv), and serum creatinine \<= 1.5 times of upper limit of normal. 5. serum hiv antigen or antibody is negative. 6. hepatitis c virus (hcv) antibody is negative, or hcv antibody is positive, but hcv-rna is negative. 7. both hbsag and hbcab for hepatitis b virus (hbv) are negative. if not, the quantification of hbv-dna needs to be \<1\*10e3 iu/ml. 8. the patient or his/her guardian must be able to understand and be willing to participate in this study, and sign the informed consent. exclusion criteria: 1. non ebv-hlh or caebv patients. 2. refractory or relapsed ebv-hlh or caebv. 3. heart function above grade ii (nyha). 4. patients suffered from other uncontrollable active infections. 5. pregnant or lactating women. 6. patients with mental disorders and cannot cooperate with the requirements of research, treatment and monitoring. 7. active visceral bleeding. 8. allergic to pd-1 monoclonal antibody. 9. patients with known autoimmune diseases. 10. participate in other clinical research at the same time. 11. the investigator judges that the patient has other reasons not suitable for this study, or participating in the study will bring great risks to the patient.
necessity for lipid lowering therapy in type 2 diabetes patients

Conditions: Type 2 Diabetes

Summary: purpose: to assess prior need for lipid lowering therapy in patients with type 2 diabetes. background/hypothesis: at present, lipid lowering therapy, usually with a hmg-coa reductase inhibitor or "statin", is recommended therapy for selected patients with type 2 diabetes mellitus (dm). the use of statins for primary prevention of cvd is not clear. some primary prevention studies have found a statistically significant benefit but others have not (cards and aspen). although low-density lipoprotein (ldl) has traditionally been a key marker of cardiovascular disease risk (cvd) risk and thus a guide to statin treatment, in recent years apolipoprotein b (apob) has emerged as an independent risk factor for cvd. in a recent study, tildesley h. et al. showed that in 500 patients with type 2 dm not on lipid lowering therapy there was discordance between ldl and apob values. specifically, it was found that among patients who fail to achieve the ldl-c target, 13% of men, 24% of women less than 50 and 13% of women greater than 50 meet the apob target. in other words, while the ldl level would indicate treatment, the apob level would not. objectives: the investigators propose to measure lipid parameters during lipid lowering therapy and compare this with lipid parameters at one and two months after discontinuation of therapy in selected patients with type 2 dm at low risk for cvd. lipid parameters to be measured include: high-density lipoprotein (hdl) - cholesterol, ldl-cholesterol, triglycerides, total cholesterol, total cholesterol: hdl-cholesterol ratio and apob. as well, a1c will be measured.


Eligibility criteria:
inclusion criteria: * ldl \< 2.5 mmol/l and total cholesterol: hdl-cholesterol ratio \< 4.0 * blood pressure ≤ 130/80 mmhg * no personal or family history of cvd * no history of proteinuria or renal failure * taking atorvastatin (lipitor) with a dosage ≤ 10 mg, equivalent dosages for other statins follow this requirement (simvastatin ≤ 20 mg, pravastatin ≤ 40 mg, rosuvastatin ≤ 5 mg, fluvastatin ≤ 40 mg and lovastatin ≤ 40 mg) * calculated by the ukpds risk engine to be low risk (risk is less than 15%) for coronary heart disease (chd), fatal chd, stroke and fatal stroke (the ukpds risk engine provides risk estimates in individuals with type 2 diabetes not known to have heart disease (1), calculating the patient's risk involves considering risk factors such as age, sex, incidence of smoking and lipid levels) exclusion criteria: * patients who do not meet the above criteria or are not willing to participate will not be included in the study

Keywords: type 2 diabetes dyslipidemia
transoral incisionless fundoplication database repository (tif)

Conditions: Gastroesophageal Reflux Disease

Summary: collect data on individuals who have a transoral incisionless fundoplication (tif) performed by physicians at indiana university for the treatment of gastroesophageal reflux disease.

collect patient information related to transoral incisionless fundoplication (tif) done for gastroesophageal reflux disease. the database information with be used for research to assess trends improve patient care.

Eligibility criteria:
inclusion criteria: * having a tif procedure completed at indiana university health, university hospital exclusion criteria: * under 13 years of age
creatine kinase versus 3d doppler for antenatal diagnosis of abnormal adherent placenta.

Conditions: Placenta Accreta

Summary: placenta accreta is a potentially life-threatening obstetric condition that requires a multidisciplinary approach to management.diagnosis of placenta accreta before delivery minimizes potential maternal or neonatal morbidity and mortality. in this study the researchers will evaluate the role and cost effectiveness of biochemical marker as creatine kinase in comparison with 3d doppler ultrasound in antenatal diagnosis of placenta accreta and its variants in patients with placenta previa totalis.

abnormal placentation poses a diagnostic and treatment challenge for all providers caring for pregnant women. as one of the leading causes of postpartum hemorrhage, abnormal placentation involves the attachment of placental villi directly to the myometrium with potentially deeper invasion into the uterine wall or surrounding organs. surgical procedures that disrupt the integrity of uterus, including cesarean section, dilatation and curettage, and myomectomy, have been implicated as key risk factors for placenta accreta(megier et al., 2000).prenatal diagnoses of placenta accreta through the use of gray-scale ultrasonography, color doppler imaging, and magnetic resonance imaging have been reported previously (chou et al., 1997). placenta increta and percreta have rarely been diagnosed antepartum, and ultrasonographic findings may provide the only objective evidence of placenta accreta.a biochemical marker for this condition would therefore be useful (ophir et al., 1999).it is critical to make the diagnosis before delivery because preoperative planning can significantly decrease blood loss and avoid substantial morbidity associated with placenta accreta (shih et al., 2009).

Eligibility criteria:
inclusion criteria: - a- pregnant lady with history of previous cesarean section or hysterotomy. b- placenta previa with its lower edge covering the scar of previous cesarean section as diagnosed by 2du/s. c- gestational age ranging from 28 wks - full term. exclusion criteria: * women with one or more of the following conditions contributing to rhabdomyolysis: 1. crush injury and prolonged surgery. 2. embolism, thrombosis, d.v.t., myocardial or brain infarction. 3. drug overdose: antipsychotics, antidepressants, hypnotics, narcotics, alcohol, halothane,salicylates. 4. excessive muscle activity as epileptic fit. 5. chronic hypertension \& pih 6. endocrine disorders: hyper-/hypothyroidism, and diabetes mellitus,history of liver disease or renal disease.
a comparison of propofol based total intravenous anesthesia and sevoflurane based balanced anesthesia on renal protection during lung transplantation under extracorporeal membrane oxygenation - a prospective, randomized trial

Conditions: Patients Undergoing Lung Transplantation Under Extracorporeal Membrane Oxygenation

Summary: the aim of this study is to investigate whether propofol based total intravenous anesthesia reduces incidence of acute kidney injury following the lung transplantation under extracorporeal membrane oxygenation


Eligibility criteria:
inclusion criteria: * sixty adults undergoing lung transplantation under extracorporeal membrane oxygenation exclusion criteria: * patient having propofol allergy, bmi \> 30 kg/m2

Keywords: propofol lung transplantation extracorporeal membrane oxygenation acute kidney injury